Subsequent trials demonstrated cardiovascular benefits: in the SUSTAIN 6 trial, semaglutide reduced major adverse cardiovascular events by 26% in high-risk patients, a finding that led to FDA approval for cardiovascular risk reduction in January 2020
doi: 10.3390/nu12103120 163 DaveNJuddJMDeckerAWinslowWSarettePVillarreal EspinosaOet al
Semaglutide mimics the action of GLP-1, a hormone that increases insulin secretion, decreases glucagon secretion, and slows gastric emptying, helping lower blood sugar levels and promote weight loss
To view or add a comment, sign in Doctoral researcher Velizar Kirilovs work on biosimilar competition has received international recognition, winning both the Best Junior Paper at the 2024 Florence Conference on IP, Competition and Innovation and the 2026 Antitrust Writing Award in the Students Awards category
non-oral contraception or backup methods are recommended during these periods
The Architectural Divide: One Molecule or Two